Parathyroid hormone (1-34) (human): Mechanistic Benchmarks in Calcium Homeostasis and Bone Research

Executive Summary: Parathyroid hormone (1-34) (human) is a synthetic peptide fragment, corresponding to the biologically active N-terminal portion of the native hormone, with a precise sequence and molecular weight of 4117.72 Da (APExBIO). It binds to PTH1R and PTH2R, demonstrating an IC₅₀ of 0.22 nM for cAMP production in transfected human kidney 293 cells, and triggers both cAMP and inositol phosphate signaling pathways (Huang et al., 2025). In vivo, it increases trabecular and cortical bone mass in dose- and time-dependent manners in Fisher 344 rats at 10–40 μg/kg/day. The peptide is highly soluble in DMSO (≥399.3 mg/mL) and water (≥19.88 mg/mL), but insoluble in ethanol. It is supplied as a high-purity (>97.8%) solid, intended for rigorous research applications in bone metabolism, kidney organoid modeling, and calcium regulation (APExBIO).

Biological Rationale

Parathyroid hormone (1-34) (human) represents the active N-terminal fragment of the full-length 84-amino acid parathyroid hormone, produced by chief cells of the parathyroid gland (APExBIO). This fragment is sufficient for full physiological activity in calcium homeostasis, as it contains all receptor-binding and signaling domains necessary for biological function. The principal targets include bone, kidney, and intestine, coordinating calcium flux among these compartments (Huang et al., 2025). Dysregulation of PTH signaling is implicated in osteoporosis, chronic kidney disease-mineral and bone disorder (CKD-MBD), and certain forms of hypoparathyroidism. Utilization of the peptide fragment allows precise modeling and modulation of these pathways in preclinical research, especially when integrated with advanced organoid and assembloid platforms. For a broader discussion of organoid model optimization using this peptide, see this guide, which is extended here with new mechanistic and quantitative benchmarks.

Mechanism of Action of Parathyroid hormone (1-34) (human)

Upon administration, Parathyroid hormone (1-34) (human) binds primarily to the parathyroid hormone 1 receptor (PTH1R), a G-protein-coupled receptor expressed on osteoblasts, renal tubular cells, and other target tissues (Huang et al., 2025). Agonist binding activates two canonical intracellular signaling pathways:

• cAMP pathway: Activation of adenylyl cyclase increases intracellular cAMP, leading to protein kinase A (PKA) activation and downstream gene expression changes.
• Inositol phosphate synthesis: Stimulation of phospholipase C results in generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), modulating calcium release from intracellular stores.

The combined actions of these pathways result in:

• Enhanced mobilization of calcium from bone via stimulation of osteoclast activity.
• Increased renal reabsorption of calcium and magnesium, particularly in distal tubules and thick ascending limb.
• Stimulation of renal 1-α-hydroxylase, increasing conversion of 25-hydroxyvitamin D to its active form, thereby augmenting intestinal calcium absorption.

These effects collectively maintain serum calcium within a narrow physiological range. For detailed mechanistic and translational insight, see this review, which this article updates with specific IC₅₀ values and context-specific solubility parameters.

Evidence & Benchmarks

• Parathyroid hormone (1-34) (human) displays an IC₅₀ of 0.22 nM for cAMP production in PTH1R-transfected human kidney 293 cells at 37°C, pH 7.4 (APExBIO).
• In vivo administration at 10 or 40 μg/kg/day subcutaneously for 4 weeks in male Fisher 344 rats induces significant, dose-dependent increases in both trabecular and cortical bone mass (see Table 2 in Huang et al., 2025).
• The peptide is soluble at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, but insoluble in ethanol; stability is maintained when desiccated at -20°C (APExBIO).
• High-purity (>97.8%) is confirmed by HPLC and mass spectrometry, supporting reproducibility in experimental workflows (APExBIO).
• Spatially patterned kidney assembloids using PTH (1-34) recapitulate key aspects of nephron maturation and function, as verified by calcium flux assays and gene expression profiling (Huang et al., 2025).

This article clarifies the direct benchmarks for cAMP and bone mass endpoints, extending the workflow recommendations in previous cell viability studies by including quantitative solubility and stability data.

Applications, Limits & Misconceptions

Primary Applications:

• Modeling of bone remodeling and osteoporosis in rodent and cell-based models.
• Regulation of calcium homeostasis in advanced kidney organoid and assembloid systems (Huang et al., 2025).
• Experimental modulation of PTH/PTHrP receptor signaling pathways in mechanistic studies.
• Validation of receptor agonism and downstream signaling (cAMP, inositol phosphate) in biosensor and reporter assays.

For advanced mechanistic insights, see this article, which this review extends by providing updated in vivo benchmarks and clarifying storage/solubility parameters.

Common Pitfalls or Misconceptions

• Not effective for diagnostic or therapeutic use in humans; for research applications only (APExBIO).
• Long-term storage of solutions at room temperature or 4°C leads to degradation; use freshly prepared aliquots and store desiccated solid at -20°C.
• Not soluble in ethanol; attempts to dissolve in this solvent result in precipitation and loss of activity.
• Peptide-induced effects in non-mammalian models may not recapitulate human PTH receptor signaling due to species-specific receptor homology.
• Results from in vitro kidney organoid models may not fully translate to adult human physiological function due to organoid immaturity (Huang et al., 2025).

Workflow Integration & Parameters

Parathyroid hormone (1-34) (human) is supplied as a lyophilized solid by APExBIO (A1129 kit), with recommended storage at -20°C in a desiccated environment. For reconstitution, dissolve in DMSO to obtain stock concentrations up to 399.3 mg/mL, or in water for immediate use at up to 19.88 mg/mL. Avoid repeated freeze-thaw cycles and discard solutions after short-term use (within 24 hours at 4°C). For cell-based assays (e.g., cAMP production in HEK293 cells), typical working concentrations range from 0.01 nM to 10 nM, depending on receptor density and assay sensitivity. In animal studies, subcutaneous administration at 10–40 μg/kg/day has been validated for bone mass endpoints in rats (Huang et al., 2025). Researchers should confirm receptor expression and optimize buffer conditions (pH 7.2–7.4) for maximal activity. For integration with kidney organoid or assembloid systems, titrate peptide concentration to mirror physiological serum PTH levels (10–70 pg/mL) as closely as possible, adjusting for model-specific uptake and degradation rates.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) is a rigorously characterized reagent for bone metabolism, osteoporosis, and kidney model research. Its high potency, specificity for PTH1R/PTH2R, and favorable solubility/stability profiles support reproducible and sensitive experimental workflows. As advanced kidney assembloid models become more physiologically relevant (Huang et al., 2025), precise modulation of calcium homeostasis with this peptide underpins both mechanistic studies and translational applications. For further detail on mechanistic precision, see Mechanistic Precision, which this article updates with new evidence from in vivo and organoid platforms.